Find Answers
to Common Questions
Welcome to the FAQ section, where common queries about MTC³’s services and offerings are addressed. This section is designed to enhance the experience by providing quick, detailed answers.
Comprehensive Answers
to Common Questions
What expert consulting services does MTC3 provide?
MTC³ delivers high-impact advisory sessions for biotech investors, early-stage founders, and commercial leaders. Services include 1:1 KOL consults, multi-expert roundtable discussions, and custom strategic advisory — all designed to accelerate clarity in dermatology, immunology, and inflammatory disease investment.
Who are the experts I’ll be speaking with?
Our expert network includes top key opinion leaders (KOLs) with clinical, regulatory, and commercial expertise. Every session is tailored — we match you with specialists who align directly to your therapeutic area, trial phase, or investment focus.
What is the typical timeline for scheduling a session?
Most expert sessions are confirmed within 1–3 weeks, depending on the scope and availability of faculty. We accommodate urgent strategic decisions, diligence requests, or preclinical reviews on an expedited basis when possible.
Can MTC3 help if I’m still shaping the question or thesis?
Yes. You don’t need a finalized scope. Many clients use our expert sessions to pressure-test early-stage strategies, evaluate clinical development options, or assess new indication pathways. Share your context and we’ll recommend a format that fits.
Do you offer expert insight outside dermatology or immunology?
While MTC³ specializes in inflammatory diseases, we maintain a vetted network of experts across oncology, rare disease, and adjacent therapeutic areas. If your question requires niche expertise, include that in your request and we’ll source the right voice.
How does MTC3 manage compliance and confidentiality?
All experts disclose relevant affiliations, and we adhere to strict confidentiality standards. We provide NDAs upon request and ensure every engagement meets the compliance expectations of biotech companies, investors, and clinical-stage teams.
Still Have Questions?
We’re Here to Help.
Contact MTC³ directly for further clarification and support.
